Najcitovanejšie publikácie

prof. MUDr. Jozef Rovenský, DrSc.

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
By: Smolen, Josef S.; Beaulieu, Andre; Rubbert-Roth, Andrea; et al.
Group Author(s): OPTION Investigators
Conference: Annual European Congress of Rheumatology (EULAR 2007) Location: Barcelona, SPAIN Date: JUN 13-16, 2007
Sponsor(s): European League Against Rheumatism
LANCET Volume: 371 Issue: 9617 Pages: 987-997 Published: MAR 22 2008
Times Cited: 828
(from All Databases)
Highly Cited Paper

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis
By: Lovell, Daniel J.; Ruperto, Nicolino; Goodman, Steven; et al.
Group Author(s): Pediat Rheumatology Collaborative; Pediat Rheumatology Int Trials Org
NEW ENGLAND JOURNAL OF MEDICINE Volume: 359 Issue: 8 Pages: 810-820 Published: AUG 21 2008
Times Cited: 332
(from All Databases)
Highly Cited Paper

Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?
By: Amital, H.; Szekanecz, Z.; Szucs, G.; et al.
ANNALS OF THE RHEUMATIC DISEASES Volume: 69 Issue: 6 Pages: 1155-1157 Published: JUN 2010
Times Cited: 171
(from All Databases)

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
By: van Vollenhoven, Ronald F.; Mosca, Marta; Bertsias, George; et al.
ANNALS OF THE RHEUMATIC DISEASES Volume: 73 Issue: 6 Pages: 958-967 Published: JUN 2014
Times Cited: 138
(from All Databases)
Highly Cited Paper

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
By: Rubbert-Roth, Andrea; Tak, Paul P.; Zerbini, Cristiano; et al.
Group Author(s): MIRROR Trial Investigators
RHEUMATOLOGY Volume: 49 Issue: 9 Pages: 1683-1693 Published: SEP 2010
Times Cited: 106
(from All Databases)

Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice
By: van der Goes, M. C.; Jacobs, J. W. G.; Boers, M.; et al.
ANNALS OF THE RHEUMATIC DISEASES Volume: 69 Issue: 11 Pages: 1913-1919 Published: NOV 2010
Times Cited: 104
(from All Databases)

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study
By: Schlesinger, Naomi; Mysler, Eduardo; Lin, Hsiao-Yi; et al.
ANNALS OF THE RHEUMATIC DISEASES Volume: 70 Issue: 7 Pages: 1264-1271 Published: JUL 2011
Times Cited: 100
(from All Databases)

prof. MUDr. Jozef Rovenský, DrSc. - významné publikácie (nad 100 citácií)

1.
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
By: Smolen, Josef S.; Beaulieu, Andre; Rubbert-Roth, Andrea; et al.
Group Author(s): OPTION Investigators
Conference: Annual European Congress of Rheumatology (EULAR 2007) Location: Barcelona, SPAIN Date: JUN 13-16, 2007
Sponsor(s): European League Against Rheumatism
LANCET Volume: 371 Issue: 9617 Pages: 987-997 Published: MAR 22 2008
Times Cited: 828
(from All Databases)
Highly Cited Paper

2.
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis
By: Lovell, Daniel J.; Ruperto, Nicolino; Goodman, Steven; et al.
Group Author(s): Pediat Rheumatology Collaborative; Pediat Rheumatology Int Trials Org
NEW ENGLAND JOURNAL OF MEDICINE Volume: 359 Issue: 8 Pages: 810-820 Published: AUG 21 2008
Times Cited: 332
(from All Databases)
Highly Cited Paper

3.
Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?
By: Amital, H.; Szekanecz, Z.; Szucs, G.; et al.
ANNALS OF THE RHEUMATIC DISEASES Volume: 69 Issue: 6 Pages: 1155-1157 Published: JUN 2010
Times Cited: 171
(from All Databases)

4.
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
By: van Vollenhoven, Ronald F.; Mosca, Marta; Bertsias, George; et al.
ANNALS OF THE RHEUMATIC DISEASES Volume: 73 Issue: 6 Pages: 958-967 Published: JUN 2014
Times Cited: 138
(from All Databases)
Highly Cited Paper

5.
Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
By: Rubbert-Roth, Andrea; Tak, Paul P.; Zerbini, Cristiano; et al.
Group Author(s): MIRROR Trial Investigators
RHEUMATOLOGY Volume: 49 Issue: 9 Pages: 1683-1693 Published: SEP 2010
Times Cited: 106
(from All Databases)

6.
Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice
By: van der Goes, M. C.; Jacobs, J. W. G.; Boers, M.; et al.
ANNALS OF THE RHEUMATIC DISEASES Volume: 69 Issue: 11 Pages: 1913-1919 Published: NOV 2010
Times Cited: 104
(from All Databases)

7.
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study
By: Schlesinger, Naomi; Mysler, Eduardo; Lin, Hsiao-Yi; et al.
ANNALS OF THE RHEUMATIC DISEASES Volume: 70 Issue: 7 Pages: 1264-1271 Published: JUL 2011
Times Cited: 100
(from All Databases)